Q&A: Genentech's new CEO on AI, IRA and radiopharma

Max Bayer

Pharma Reporter

Genentech and Roche are pretty much the only two companies that Ashley Magargee knows. The biopharma veteran has spent two decades at both (including before …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Q&A: Genentech's new CEO on AI, IRA and radiopharma

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Merck, Daiichi Sankyo detail Phase 2 ADC results in small cell lung cancer, bispecific combo strategy

Investors pour $370M+ into Ken Song's autoimmune biotech after his RayzeBio success

Summit's Phase 3 data back up biotech's boasts of beating Keytruda in lung cancer

Terns’ oral GLP-1 passes Phase 1 test with promising weight loss after one month

Relay Therapeutics reports positive PFS data for its PI3Kα inhibitor combo in breast cancer

Eli Lilly invests in Superluminal's $120M Series A round as AI-focused startups eye the clinic

Q&A: Genen­tech's new CEO on AI, IRA and ra­dio­phar­ma

Pharma Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Q&A: Genentech's new CEO on AI, IRA and radiopharma